Universal Anti-CD22 chimeric antigen receptor engineered immune cells
Patent Information
- Application Number
- IN201917039090
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-03-31
- Filing Date
- 2019-09-27
- Publication Date
- 2026-09-30
- Estimated Expiration
- 2038-03-30
AI Technical Summary
Current immunotherapy methods for hematological cancers, such as those using CAR-T cells, face challenges including inefficiency against aggressive forms, cancer cell escape through antigen downregulation, and adverse effects like cytokine release syndrome, particularly in patients with altered immune systems or under immunosuppressive therapies.
Development of Universal Chimeric Antigen Receptor T cells (UCART22) engineered with a deleted TRAC gene, additional gene inactivations like CD52, and a safety marker, which are resistant to immunosuppressive drugs and designed to target CD22 with a specific CAR structure including a hinge domain from CD8alpha and intracellular signaling domains, allowing controlled activity and reduced cytokine release.
UCART22 cells demonstrate enhanced efficacy against refractory and relapsed hematological cancers with reduced cytokine release and mild graft-versus-host disease, maintaining activity in the presence of immunosuppressive drugs, thereby offering a safer and more effective treatment option.
Abstract
Description
The present invention generally relates to the field of immunotherapy, and more specifically to Universal chimeric antigen receptor T cells specific for CD22 (UCART22) that are engineered human primary immune cells comprising at least one edited gene, preferably a gene coding a TCR subunit or a CD52 gene, and a Chimeric Antigen Receptors (CAR) specific for the cluster of differentiation 22 (CD22), (CAR CD22), and to methods for engineering said cells. The invention further relates to UCART 22 for their use in patients who may or may not be the initial donor of cells ("allogenic" or "autologous" CD22 CAR engineered primary human immune cells) as a treatment for relapse refractory hematological cancers. The cells expressing a CD22 according to the invention are particularly efficient and safe for immunotherapy in particular against aggressive or relapsed cancer.Background of the inventionMore than 45,000 deaths were expected from hematological cancer (non-Hodgkin's lymphoma, leukemia) in the United States in 2000 (Greenlee et al., CA Cancer J. Clin., 50:7-33 (2000)). The numbers published in 2014 were similar and despite advances in treatments such as chemotherapy, the prognosis for such cancers remains basically unchanged. (E K Mai, U Bertsch, J D rig, C Kunz, M Haenel, I W Blau, M Munder, A Jauch,B Schurich, T hearted shear, M Merz, B Hügle-Doerr, A seckinger, D Hose, J Hillengass, MS Raab, K Besides, HW Lindemann, M Zeis, C Gerecke, ICJ Schmidt-Wolf, K Weisel, C. Scheid, H Salwender and H Goldschmidt. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (path) in newly diagnosed multiple myeloma. Leukemia (19 March 2015) | doi: 10.1038 / leu.2015.80.Unique among the new investigational treatments for these hematologic cancers is the genetic modification of cells with cytolytic capacity such as T cells through the gene-transfer of a chimeric antigen receptor (CAR) (Jena, Dotti et al. 2010).CARs are synthetic receptors consisting of a targeting moiety that is associated with one or more signaling intracellular domains in a single molecule or in multiple transmembrane domains forming a multimer. In particular CAR, the binding moiety consists of an antigen-binding domain from a single-chain antibody (scFv), comprising the variable fragments of a monoclonal antibody joined by a linker. Binding moieties based on receptor or ligand domains have also been used successfully to prepare a CAR.Signaling domains from co-stimulatory molecules of the T cell receptor (TCR), as well as particular transmembrane and hinge domains have been added to form CARs of second and third generations, leading to successful therapeutic trials in humans. In these studies, T-cells from a patient suffering a hematological ("liquid") cancer were redirected against malignant cells expressing for example CD19 or CD22 (June et al., 2011, Haso et al., 2013) and reinjected into the same patient. (Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013 Feb 14;121(7):1165-74. doi: 10.1182 / blood-2012-06-438002. Epub 2012 Dec 14).Methods allowing immune cells from one individual to be engineered before reinjection to the same individual—usually suffering from a cancer- are not well adapted in particular for aggressive forms of cancers that may be a race against time. Moreover, such method may be problematic or uncertain in patient whose immune system is altered.To palliate this problem, immunotherapy using CAR-expressing so called "allogeneic" T cells (also called universal or "off the shelf" T cells) was recently implemented and the two first patients treated with such cells are still in remission about two years after treatment.Nevertheless, there are still aspects of such therapy that may be improved, such as efficiency in the presence of anti-T cell drugs, efficiency against escaping cancer cells, persistence, means of control, etc. Indeed, it seems that cancer cells - by downregulating the expression of surface antigen recognized by CARs, may escape the treatment and subsist, despite the persistence of redirected immune in treated patients.Further, one the primary adverse, and sometimes lethal, effect observed in patients treated either with autologous or allogeneic T cells, is the cytokine release syndrome.Thus, there is still a need for developing efficient and safe treatments for these pathologies, in particular for their aggressive or refractory / relapsed forms of hematological cancers.BRIEF SUMMARY OF THE INVENTIONHere, the inventors have developed a new efficient treatment ("UCART22") comprising engineered primary human T cell with at least a deletion of the TRAC gene, endowed with a chimeric antigen receptor targeting CD22 and a safety marker allowing the number of said cells to be controlled in vivo and consequently the activity of said cells.In the new efficient treatment ("UCART22") comprising engineered primary human T cell with at least a deletion of the TRAC gene, at least one additional deletion in CD52, dCK, beta2microglobulin are gene is contemplated.These new UCART22 are particularly efficient for adoptive transfer in a patient suffering a CD22 mediated pathology, whether or not said patient is the initial donor of immune cells and whether or not said patient is already under therapy that affects immunity.UCART 22 cells of the invention are resistant to at least one chemical or antibody drug usually used to treat CD22-mediated pathology, such as Campath and / or Purine nucleotide analogs (PNAs). UCART 22 cells of the invention can survive and be active in the presence of said drug used at a dose that kills more than 80% of the cells.Significant and unexpected clinical advantages of the engineered isolated primary immune cells UCART 22 are observed, including low cytokine release, no or very mild graft versus host disease and still a significant activity against the refractory relapsed forms of hematological cancer cells.Other advantages will be disclosed in this study.This study which provides1. An engineered human T Cell Receptor Knock Out (TCR KO) cell endowed with a Chimeric Antigen Receptor (CAR) specific for CD22 (UCART 22), a safety switch, preferably expressed at the cell surface, said anti-CD22 CAR (CD22 CAR) comprising:i) at least one extracellular domain comprising :- a hinge domain from CD8alpha,- an antigen binding domain specific for CD22, optionally a leader sequence,ii) a transmembrane domain from CD8alpha, andiii) an intracellular signaling domain said CD22 CAR having a polypeptide sequence with at least 80% identity with SEQ ID N°15,said safety switch comprising :- a RQR8 temporarily linked to the CD22 CAR by a peptide 2A, or- at least two rituximab mAb-specific epitopes, preferably located between the VH and the Hinge domain, or 3 rituximab mAb-specific epitopes or 3 rituximab mAb-specific epitopes and a QBEN-10 mAb-specific epitopes linked to the CD22 CAR.2. The UCART 22 of embodiment 1 wherein a polynucleotide sequence having at least 80% identity with SEQ ID N°11 is inserted into the genome, and further comprising an inactivated TRAC gene with an insertion, a deletion or a mutation within SEQ ID N°18, withundetectable level of T Cell Receptor (TCR) at the cell surface as measured by flow cytometry, and undetectable level of off site events as measured by guide sequence technique.The UCART22 according to 2 wherein said anti-CD22 CAR is inserted preferably into the TRAC gene, preferably with SEQ ID N°18.3. The UCART22 according to any one of embodiment 1 to 2 comprising another inactivated gene selected from dCK gene, B2M gene, CD52 gene, preferably CD52 gene.4. The UCART22 according to any one of embodiment 1 to 3 wherein and at least one additional gene is inactivated, said gene is selected from a gene encoding aryl hydrocarbon receptor (AHR), Transforming growth factor beta receptor) (TGF beta receptor), Interleukin 10 receptor (IL-10 R), Program cell death protein 1, a combination thereof.5. The UCART22 according to any one of embodiment 1 to 4 wherein a gene encoding beta2Microglobulin (B2M), is inactivated.6. The UCART22 according to any one of embodiment 1 to 5 wherein a gene encoding aryl hydrocarbon receptor (AHR), is inactivated.7. The UCART22 according to any one of embodiment 1 to 6 wherein a gene encoding Transforming growth factor beta receptor) (TGF beta receptor), is inactivated.8. The UCART22 according to any one of embodiment 1 to 7 wherein a gene encoding Interleukin 10 receptor (IL-10 R), is inactivated.9. The UCART22 according to any one of embodiment 1 to 8 wherein a gene encoding Program cell death protein 1 (PD1), is inactivated.5. The UCART22 according to any one of embodiment 1 to 4 comprising an additional scfv specific for any one of the following tumor-associated surface antigens selected from CD19, CD20, CD30, a major histocompatibility complex (MHC) molecule, an Immunoglobulin (Ig), CD3, CD5, CD34, CD79, preferably CD79b, CD138, B7-1 (CD80), BCMA (CD269, TNFRSF 17), FLT-3, or PAX5, preferably CD19.6. The UCART22 according to any one of embodiment 1 to 5 wherein said CD22CAR further comprises an antigen binding domain specific for CD19 or wherein said UCART 22 further comprises a CD19CAR, preferably a CD19 CAR having at least 80% identity with SEQ ID N°25 or a SEQ ID N°26.7. The UCART22 according to any one of embodiment 1 to 5 wherein the anti-CD22 CAR is a single-chain CAR or a multi-chain CAR.8. The UCART22 according to any one of embodiment 5 or 6 wherein the anti-CD19 CAR is a single-chain CAR or a multi-chain CAR.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD19.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD20.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD30.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for a major histocompatibility complex (MHC) molecule.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for an Immunoglobulin (Ig).The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD3.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD5.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD34.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chainCAR comprising an additional scfv specific for CD79, preferably CD79b.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chainCAR comprising an additional scfv specific for CD138.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chainCAR comprising an additional scfv specific for CD80.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for BCMA (CD269).The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for TNFRSF 17,The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for FLT-3.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD19.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR, comprising an additional scfv specific for CD79 a or CD79b.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD20.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD30.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for a major histocompatibility complex (MHC) molecule.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for an Immunoglobulin (Ig).The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD3.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD5.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD34.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD138.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD80.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for BCMA (CD269).The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for TNFRSF 17,The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for FLT-3.- 9. A population of UCART cells comprising the UCART 22 according to any one of embodiment 1 to 8.10. The population of UCART cells according to embodiment 9 comprising a UCART 19, preferably a UCART19 expressing an anti-CD19 CAR comprising a sequence of SEQ ID N°25 or SEQ ID N°26 at the cell surface.11. A kit comprising a UCART 22 and a UCART19 for a successive (at least once) or a concomitant or a successive (at least once) and then concomitant administration in a patient in need thereof.12. The kit of embodiment 11 wherein the UCART 19 is used first at least once, twice, three, four or several times, and then the UCART 22, alone or with the UCART19.13. The kit of embodiment 11 or 12 wherein the UCART 22 is used first at least once, twice, three, four or several times, and then the UCART 19, alone or with the UCART22.14. The kit according to any one of embodiment 11 to 13 further comprising a lymphodepleting treatment, administered before the UCART.15. The kit according to any one of embodiment 11 to 14 wherein lymphodepletion is achieved using fludarabine and cyclophosphamide, preferably fludarabine 25 mg / m2 i.v. × 5 doses on days -6 to -2 and cyclophosphamide 60 mg / kg i.v. for 1 dose on day -5.16. The kit according to any one of embodiment 11 to 15 comprising at least one other UCART cell directed against a cancer antigen selected from CD79a, CD79b, CD20, CD30, CD52, CD40, CD80, CD86, CD74, VEGF.17. A pharmaceutical composition comprising the UCART 22 according to any one of embodiment 1 to 8 or a population of cells comprising said UCART 22 according embodiment 9 or 10 and a pharmaceutically acceptable excipient.18. The pharmaceutical composition of embodiment 17 further comprising a Bryostatin, preferably Bryostatin-1.19. The pharmaceutical composition of embodiment 17 or 18 or the kit according to any one of embodiment 11 to 16 for its use as a medication for preventing or treating a patient suffering a CD22+-mediated cancer or a CD22+-mediated inflammatory disease.20. The pharmaceutical composition of according to any one of embodiment 17 to 18 or the kit according to any one of embodiment 11 to 16 for its use as a medication for preventing or treating a patient suffering a CD19+-mediated cancer or a CD19+-mediated inflammatory disease.21. The pharmaceutical composition of according to any one of embodiment 17 to 18 or the kit according to any one of embodiment 11 to 16 for its use as a medication for preventing or treating a patient suffering a CD19+CD22+-mediated cancer or a CD19+CD22+-mediated inflammatory disease.22.The pharmaceutical composition of according to any one of embodiment 17 to 18 or the kit according to any one of embodiment 11 to 16 for its use according any one of embodiment 19 or 21, wherein treating a patient comprises a step of administering the pharmaceutical composition at least twice (re dosing) to avoid a relapse / refractory development of the cancer.23. The pharmaceutical composition of according to any one of embodiment 17 to 18 or the kit according to any one of embodiment 11 to 16 for its use according any one of embodiment 19 or 21, for the treatment of a CD22-mediated hematological cancer selected from lymphoma, Hodgkin lymphoma, non Hodgkin lymphoma, leukemia, multiple myeloma, B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia (ALL), and Burkitt's lymphoma, acute lymphocytic cancer, acute myeloid leukemia, preferably a CD22 expressing hematological cancer selected from (lymphoma, Hodgkin lymphoma, non Hodgkin lymphoma, leukemia, multiple myeloma, B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia (ALL), and Burkitt's lymphoma, acute lymphocytic cancer, acute myeloid leukemia, more preferably a relapse refractory CD22-expressing hematological cancer, even more preferably an aggressive form of said CD22-related hematological cancer.24. The pharmaceutical composition of according to any one of embodiment 17 to 18 or the kit according to any one of embodiment 11 to 16 for its use according any one of embodiment 20 or 21 for the treatment of a CD19-mediated hematological cancer selected from lymphoma, Hodgkin lymphoma, non Hodgkin lymphoma, leukemia, multiple myeloma,B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia (ALL), and Burkitt's lymphoma, acute lymphocytic cancer, acute myeloid leukemia, preferably a CD19 expressing hematological cancer selected from (lymphoma, Hodgkin lymphoma, non Hodgkin lymphoma, leukemia, multiple myeloma, B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia (ALL), and Burkitt's lymphoma, acute lymphocytic cancer, acute myeloid leukemia, more preferably a relapse refractory CD19-expressing hematological cancer, even more preferably an aggressive form of said CD19-related hematological cancer.-25. The pharmaceutical composition of according to any one of embodiment 17 to 18 or the kit according to any one of embodiment 11 to 16 for its use according any one of embodiment 19 to 22 for the treatment of a relapse or refractory expressing B ALL, preferably as a pediatric indication.26. The pharmaceutical composition of according to any one of embodiment 17 to 18 or the kit according to any one of embodiment 11 to 16 for its use according any one of embodiment 19 to 25, wherein treating a patient comprises administering at least one monoclonal antibody (mAb), preferably QBEN 10 and or Rituximab, in a patient, at a dose allowing contacting said UCART22 with at least one specific mAb.Embodiments for a CD22 CARThe invention provides an anti-CD22 CAR comprising a hinge domain selected from FcRIIIα, CD8alpha, IgG1, IgG4, and PD1, preferably from CD8 alpha or IgG4.The ANTI-CD22 CAR according the above wherein a scfv specific for CD22 comprising a VH and a VL linked to each other by a linker L1, preferably a linker comprising 1 to 3 "GGGGS" motif, more preferably one GGGGS" motif.The ANTI-CD22 CAR according to any one of the above wherein said scfv specific for CD22 is linked to a transmembrane domain by a hinge selected from a hinge from FcRIIIα, CD8alpha, IgG1, preferably from CD8 alpha.The ANTI-CD22 CAR according to any one of the above comprising an intracellular domain, said an intracellular domain comprising a CD3zeta signaling domain and a 4-1BB signaling domain.The anti-CD22 CAR as any one of the above wherein the anti-CD22 CAR comprises at least one, preferably two, three or four monoclonal antibody (mAb)-specific epitopes, preferably two inserted into the linker L of the scfv specific for CD22 and / or into the hinge.The anti-CD22 CAR as any one of the above, wherein the mAb-specific epitope is a polypeptide selected from: CPYSNPSLC, NSELLSLINDMPITNDQKKLMSNN, CQFDLSTRRLKC,GQN DTSQTSSPS, preferably ELPTQGTFSNVSTNVSPAKPTTTA and / or CPYSNPSLC (SEQ ID N°19).The invention provides a polynucleotide encoding an ANTI-CD22 CAR according to any one of the above or a polynucleotide having at least 80% identity with said a polynucleotide encoding an ANTI-CD22 CAR, a vector comprising a polynucleotide according to any one of the obove polynucleotides.as disclosed herein below other genes are edited in said UCART22 in particular the dCK gene, the B2M gene, CD52 gene.UCART PROVIDEDThe UCART22 as above is provided wherein and at least one additional gene is edited or engineered, said gene is selected from a gene encoding aryl hydrocarbon receptor (AHR), Transforming growth factor beta receptor) (TGF beta receptor), Interleukin 10 receptor (IL- 10 R), Program cell death protein 1, a combination thereof.The UCART22 as above wherein and at least one additional gene comprises a mutation, a deletion or an insertion inactivating its activity and / or expression said gene selected from a gene encoding aryl hydrocarbon receptor (AHR), Transforming growth factor beta receptor) (TGF beta receptor), Interleukin 10 receptor (IL-10 R), Program cell death protein 1, a combination thereof.The UCART22 as above wherein and at least one additional gene comprises a mutation, a deletion or an insertion inactivating its activity and / or expression said gene selected from a gene encoding aryl hydrocarbon receptor (AHR), Transforming growth factor beta receptor) (TGF beta receptor), Interleukin 10 receptor (IL-10 R), a combination thereof.The UCART22 as above wherein and at least one additional gene comprises a mutation, a deletion or an insertion inactivating its activity and / or expression said gene selected from a gene encoding Transforming growth factor beta receptor) (TGF beta receptor), Interleukin 10 receptor (IL-10 R), Program cell death protein 1, a combination thereof.The UCART22 as above wherein and at least one additional gene comprises a mutation, a deletion or an insertion inactivating its activity and / or expression said gene selected from a gene encoding aryl hydrocarbon receptor (AHR), Interleukin 10 receptor (IL-10 R), Program cell death protein 1, a combination thereof.The UCART22 as above wherein and at least one additional gene comprises a mutation, a deletion or an insertion inactivating its activity and / or expression said gene selected from a gene encoding aryl hydrocarbon receptor (AHR), Transforming growth factor beta receptor) (TGF beta receptor), Program cell death protein 1, a combination thereof.Gene in which said CAR may be inserted are described below in Table 9Table 9: List of genes encoding immune checkpoint proteins that may be inactivated according to the present invention in the CD22 CAR engineered T cells of the inventionIn bold are the preferred gene inactivated in the UCART of the inventionThe UCART22 as above comprising an anti-CD22 CAR (UCART22) according to any one of the above and a polynucleotide coding said anti-CD22 CAR (UCART22) inserted into the genome, into the CD25 gene.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR or a multi-chain CAR.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for any one of the following tumor-associated surface antigens selected from CD19, CD20, CD30, a major histocompatibility complex (MHC) molecule, an Immunoglobulin (Ig), CD3, CD5, CD34, CD79, preferably CD79b, CD138, B7-1 (CD80), BCMA (CD269, TNFRSF 17), FLT-3, or PAX5, preferably CD19.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD19.The UCART22 according to any one of the above expressing an anti-CD22 CAR and an anti-CD19CAR, preferably of SEQ. ID N°94 or of SEQ ID N°95.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD20.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD30.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for a major histocompatibility complex (MHC) molecule.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for an Immunoglobulin (Ig).The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD3.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD5.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD34.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD79, preferably CD79b.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD138.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for CD80.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for BCMA (CD269).The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for TNFRSF 17,The UCART22 according to any one of the above wherein the anti-CD22 CAR is a single-chain CAR comprising an additional scfv specific for FLT-3.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD19.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR, comprising an additional scfv specific for CD79 a or CD79b.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain (mc) CAR comprising an additional scfv specific for CD19.The UCART22 according to any one of the above expressing an anti-CD22 mcCAR and an anti-CD19CAR, preferably of SEQ ID N°94 or of SEQ ID N°95.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD20.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD30.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for a major histocompatibility complex (MHC) molecule.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for an Immunoglobulin (Ig).The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD3.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD5.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD34.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD138.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for CD80.The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for BCMA (CD269).The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for TNFRSF 17,The UCART22 according to any one of the above wherein the anti-CD22 CAR is a multi-chain CAR comprising an additional scfv specific for FLT-3.A population of cells comprising the UCART 22 according to any one of the above.A population of cells comprising the UCART 22 according to any one of the above and wherein cells expressing said anti-CD22 CAR also express an anti-CD19 CAR, preferably said anti-CD19 CAR comprises a sequence of SEQ. ID N°25 or SEQ. ID N°26 at the cell surface.A CD22 CAR T cell (UCART22), optionally combined to a protein kinase C inhibitor such as bryostatin 1 as a pharmaceutical composition of the invention, is particularly useful in for the treatment of CLL, ALL, Multiple myeloma, (MM), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), especially refractory / relapse ALL, refractory / relapse CLL and or aggressive forms of these diseases, more preferably refractory or relapse B-ALL.A CD22 CAR T cell (UCART22), derived from m971, optionally combined to a protein kinase C inhibitor such as bryostatin 1 as a pharmaceutical composition of the invention, is particularly useful in for the treatment of CLL, ALL, Multiple myeloma, (MM), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), especially refractory / relapse ALL, refractory / relapse CLL and or aggressive forms of these diseases, more preferably refractory or relapse B-ALL.The engineered immune cells of the present invention not only display high level of in vivo activity toward malignant cells, less cytokine release but also their number and activity is controlled conferring safety and efficiency for immunotherapy.The present invention provides an engineered human T Cell Receptor Knock Out (TCR KO) cell endowed with a Chimeric Antigen Receptor specific for CD22 (CD22 CAR) (UCART 22), preferably expressed at the cell surface,wherein said CD22 CAR comprises:i) at least one extracellular domain comprising :- a hinge domain from CD8alpha,- an antigen binding domain specific for CD22, optionally a leader sequence,ii) a transmembrane domain from CD8alpha, andiii) an intracellular signaling domain.said UCART22 comprising at least one additional edited gene, preferably a deletion in the CD52 gene.The present invention also provides the UCART CD22 as above wherein the antigen binding domain comprises a scfv specific for CD22, derived from a m917 antibody(m971), preferably said scfv comprises a sequence selected from SEQ ID N° 12, SEQ ID N° 13, SEQ ID N° 14 and from SEQ ID N° 15, more preferably a sequence from SEQ ID N°.15.In one embodiment the present invention also provides an engineered human T Cell Receptor Knock Out (TCR KO) cell endowed with a Chimeric Antigen Receptor specific for CD22 (CD22 CAR) (UCART 22), preferably expressed at the cell surface,wherein said CD22 CAR comprises:i) at least one extracellular domain comprising :- a hinge domain from CD8alpha,- an antigen binding domain specific for CD22, optionally a leader sequence,ii) a transmembrane domain from CD8alpha, andiii) an intracellular signaling domain.said UCART22 comprising at least one additional edited gene, preferably a deletion in the CD52 geneand wherein the antigen binding domain comprises a scfv specific for the distal part ofCD22, said CAR having a SEQ IDN°20.The UCART CD22 according to the above comprising the following sequences :GTDFTLTISSLQAEDFATYYCQQSYSIPQTFGQGTKLEIK or having 80 to 99 % homology with each of said sequences.The present invention also provides a UCART 22 as above comprising a polypeptide of SEQ ID NO15 and a safety switch comprising :. a RQR8 temporarily linked to the CD22 CAR by a peptide 2A or. at least two rituximab mAb-specific epitopes, preferably 3 rituximab mAb-specific epitopes and more preferably 3 rituximab mAb-specific epitopes and a QBEN-10 mAb-specific epitopes linked to the CD22 CAR.[allowing both sorting and / or depletion of the immune cells endowed with said CD22 CAR].The present invention also provides a UCART 22 as above comprising at least one additional edited gene, preferably a deletion in CD52 gene, or in a dCK gene or a deletion in a beta2 microglobulin gene or in CTIIA gene, even more preferably a deletion in CD52 gene, and / or an insertion in the HIF-1alpha gene, conferring resistance to hypoxia.The present invention provides a UCART 22 as above comprising a deletion in CD52 gene, in combination with alemtuzumab.The present invention also provides a UCART 22 as above wherein said CD22 CAR is expressed under hypoxia (low O2 concentration that is less than 5% O2, preferably less than 1% O2).The present invention also provides a UCART 22 as above comprising a polynucleotide encoding a polypeptide comprising a CD22 CAR and a safety switch. In a preferred embodiment, the present invention provides a UCART 22 as above comprising a polynucleotide of SEQ ID NO. 22 and of SEO IDN°18 in the same gene, preferably in the TRAC gene.The present invention also provides a UCART 22 as above comprising a polynucleotide encoding a polypeptide comprising a CD22 CAR and a safety switch. In a preferred embodiment, the present invention provides a UCART 22 as above comprising a polynucleotide of SEQ ID NO. 20 and of SEO IDN°18 in the same gene, preferably in the TRAC gene.The present invention provides a population of cells comprising a UCART 22 as above.The present invention provides a pharmaceutical composition comprising either the UCART 22 as above or a population of cells comprising said UCART 22 any of the above and a pharmaceutically acceptable excipient.In particular embodiments, a pharmaceutical composition comprising the UCART 22 according to the invention or a population of cells comprising said UCART 22 incombination with a UCART CD19 and a pharmaceutically acceptable excipient is provided. UCART 19 and UCART 22 may be given at the same time, concomitantly or successively starting by UCART 19 or by UCART 22 as a function of CD19 and CD22 expression level a cancer cells of patients.In particular embodiments, a pharmaceutical composition comprising the UCART 22 / 19 or UCART 19 / 22 (bispecific CAR single chain or multichain CAR or cells expressing both CD19CAR and CD22 CAR) and a pharmaceutically acceptable excipient, is provided. The present invention provides a pharmaceutical composition as above further comprising a compound of the bryostatin family, preferably bryostatin 1.The present invention provides a therapeutically effective amount of UCART 22 as above or of the pharmaceutical composition comprising said UCART 22 as above for use as a medication for treating a patient.The present invention provides a therapeutically effective amount of UCART 22 as above or of the pharmaceutical composition as above for use as a medication for treating a patient wherein treating a patient comprises administering at least two times (re dosing) said therapeutically effective amount of UCART CD22 or said pharmaceutical composition for avoiding a relapsing.In a particular embodiment, the present invention provides a UCART CD22 according to any one of the above or the pharmaceutical composition according to any one of the above for use as a medication for treating a patient wherein treating a patient comprises administering a UCART 22 as above or a pharmaceutical composition as above at least two times for avoiding the relapsing.The present invention provides a therapeutically effective amount of UCART 22 as above or of the pharmaceutical composition as above for use as a medication for treating a patient as above for the treatment of a CD22-related pathology, preferably a CD22-related B-cell malignancy (eg CD22-related hematological cancer).In a particular embodiment, the present invention provides:The therapeutically effective amount of UCART 22 as above or of the pharmaceutical composition as above for use as a medication for the treatment of a hematological cancer such as a hematological cancer selected from (lymphoma, Hodgkin lymphoma, non Hodgkin lymphoma, leukemia, multiple myeloma, B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia (ALL), and Burkitt's lymphoma, acute lymphocytic cancer, acute myeloid leukemia, preferably a CD22-expressing hematological cancer, more preferably a relapse refractory CD22-expressing hematological cancer, even more preferably an aggressive form of said CD22-related hematological cancer.Preferably the UCART22 is used for treating patients with relapse refractory B ALL.The present invention provides a therapeutically effective amount of UCART 22 as above or of a pharmaceutical composition as above for use as a medication for treating a patient wherein said patient suffers from a cancer selected from alveolar rhabdomyosarcoma, bladder cancer (e.g., bladder carcinoma), bone cancer, brain cancer (e.g., medulloblastoma), breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, cancer of the gallbladder, cancer of the pleura, cancer of the nose, cancer of the nasal cavity, cancer of the middle ear, cancer of the oral cavity, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, fibrosarcoma, gastrointestinal carcinoid tumor, head and neck cancer (e.g., head and neck squamous cell carcinoma), hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer (e.g., non-small cell lung carcinoma), malignant mesothelioma, mastocytoma, melanoma, nasopharynx cancer, ovarian cancer, pancreatic cancer, peritoneum cancer, omentum cancer, mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, small intestine cancer, soft tissue cancer, solid tumors, stomach cancer, testicular cancer, thyroid cancer, ureter cancer.The present invention provides:1. An engineered human T Cell Receptor Knock Out (TCR KO) cell endowed with a Chimeric Antigen Receptor (CAR) specific for CD22 (UCART 22), preferably expressed at the cell surface,wherein said anti-CD22 CAR comprises:i) at least one extracellular domain comprising :- a hinge domain from CD8alpha,- an antigen binding domain specific for CD22, optionally a leader sequence,ii) a transmembrane domain from CD8alpha, andiii) an intracellular signaling domain.said UCART22 comprising at least one additional edited gene, preferably a CD52 inactivated gene, a dCK inactivated gene, a beta 2 microglobulin inactivated gene or an inserted HIF-1alpha gene.2. The UCART CD22 according to 1 wherein the antigen binding domain comprises a scfv specific for CD22, said scfv is derived from a m917 antibody (m971), preferably said scfv comprises a sequence selected from SEQ ID N° 12, SEQ ID N° 13, SEQ ID N° 14 or from SEQ ID N° 15, more preferably a sequence from SEQ ID N°. 15.3. The UCART 22 according to any one of 1 to 2 comprising a polypeptide of SEQ ID NO15 and a safety switch, said safety switch comprising :- a RQR8 temporarily linked to the CD22 CAR by a peptide 2A,- at least two rituximab mAb-specific epitopes, preferably 3 rituximab mAb-specific epitopes and more preferably 3 rituximab mAb-specific epitopes and a QBEN-10 mAb- specific epitopes linked to the CD22 CAR[allowing both sorting and / or depletion of the immune cells endowed with said CD22 CAR].4. The UCART 22 according to any one of 1 to 3 comprising a CD52 inactivated gene, even more preferably a CD52 inactivated gene and HIF-1alpha inserted gene conferring resistance alemtuzumab and to hypoxia.5. The UCART 22 according to any one of 1 to 4 wherein said anti-CD22 CAR is expressed at the cell surface under low O2 concentration( <5% O2).6. The UCART 22 according to any one of 1 to 5 comprising a polynucleotide encoding a polypeptide comprising an anti-CD22 CAR as in 1 to 5.The UCART 22 according to any one of the above comprising an anti-CD22 CAR at the cell surface, a polynucleotide encoding said anti-CD22 CAR inserted into the TRAC gene and an exogenous polynucleotide sequence encoding IL-12 inserted into the CD25 genomic sequence, the B2M genomic sequence or into the PD1 genomic sequence.The UCART 22 according to any one of the above comprising an anti-CD22 CAR at the cell surface, a polynucleotide encoding said anti-CD22 CAR inserted into the TRAC gene and an exogenous polynucleotide sequence encoding IL-12 inserted into the CD25 genomic sequence or into the PD1 genomic sequence and further comprising genomic KO gene selected from IL-10Receptor, TGFbeta receptor, TIM-3, LAG-3, (see table 9 above).7. The UCART 22 according to any one of 1 to 6 further comprising a polynucleotide of SEQ ID NO. 22, preferably comprising a sequence of SEO ID N°18 and 22 in the same TRAC gene.8. A population of cells comprising said UCART 22 according to any one of 1 to 7.9. A pharmaceutical composition comprising the UCART 22 according to any one of 1 to 7 or a population of cells comprising said UCART 22 according to 8 and a pharmaceutically acceptable excipient.10. The pharmaceutical composition according to 9 further comprising a bryostatin, preferably bryostatin-1.11. A therapeutically effective amount of UCART 22 according to any one of 1 to 7 or of the pharmaceutical composition according to 9 or 10 for use as a medication for treating a patient.12. The therapeutically effective amount of UCART 22 according to any one of 1 to 7 or of the pharmaceutical composition according to 9 or 10 for use as a medication for treating a patient according to 11 wherein treating a patient comprises administering at least two times (re dosing) said therapeutically effective amount of UCART CD22 or said pharmaceutical composition for avoiding a relapsing.13. The therapeutically effective amount of UCART 22 according to any one of 1 to 7 or of the pharmaceutical composition according to 9 or 10 for use as a medication for treating a patient according to 11 or 12 for the treatment of a CD22-related pathology, preferably a CD22-related B-cell malignancy.14. The therapeutically effective amount of UCART 22 according to any one of 1 to 7 or of the pharmaceutical composition according to 9 or 10 for use as a medication for treating a patient according to any one of 11 to 13 for use in the treatment of a hematological cancer selected from (lymphoma, Hodgkin lymphoma, non Hodgkin lymphoma,leukemia, multiple myeloma, B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia (ALL), and Burkitt's lymphoma, acute lymphocytic cancer, acute myeloid leukemia, preferably a CD22-expressing hematological cancer, more preferably a relapse or refractory CD22-expressing hematological cancer, even more preferably an aggressive form of said CD22-related hematological cancer.15. The therapeutically effective amount of UCART 22 according to any one of 1 to 7 or of the pharmaceutical composition according to 9 or 10 for use as a medication for treating a patient according to any one of 11 to 13 for use in the treatment of relapsed and / or refractory CD22 positive B-ALL.16. The therapeutically effective amount of UCART 22 according to any one of 1 to 7 or of the pharmaceutical composition according to 9 or 10 for use as a medication for treating a patient according to any one of 11 to 13 wherein said patient suffers from a cancer, preferably mediated by CD22+cells, selected from alveolar rhabdomyosarcoma, bladder cancer (e.g., bladder carcinoma), bone cancer, brain cancer (e.g., medulloblastoma), breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, cancer of the gallbladder, cancer of the pleura, cancer of the nose, cancer of the nasal cavity, cancer of the middle ear, cancer of the oral cavity, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, fibrosarcoma, gastrointestinal carcinoid tumor, head and neck cancer (e.g., head and neck squamous cell carcinoma), hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer (e.g., non-small cell lung carcinoma), malignant mesothelioma, mastocytoma, melanoma, nasopharynx cancer, ovarian cancer, pancreatic cancer, peritoneum cancer, omentum cancer, mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, small intestine cancer, soft tissue cancer, solid tumors, stomach cancer, testicular cancer, thyroid cancer, ureter cancer, preferably liver cancer and lung cancer.Brief description of the figuresFigure 1: Schematic representation of an engineered immune cell according to the inventionThe engineered immune cell presented in figure 1 may be a T-cell endowed with a polynucleotide encoding a CAR of the invention. This T-cell is further engineered to allow a better and safer engraftment into the patient. X, or Y is an edited gene that may be mutated, deleted and / or having an insertion. For instance a gene expressing a component of the T cell receptor (TCR) for example the TCRalpha or TCRbeta may be deleted or may comprise an insertion, Y may be a gene involved into the sensitivity of T-cells to immune-suppressive drugs like dCK (with respect to resistance to purine nucleotide analogues) or CD52 (with respect to Campath) or HPRT (with respect to 6-Thioguanine).Figure 2: Representation of a single chain and of a multichain CD22 CARFigure 2 illustrates examples of CD22 CAR according to the invention, comprising a scfv specific for CD22, optionally comprising a safety switch, a hinge and a transmembrane domain from CD8 alpha, an intracellular domains from 4-1BB and CD3 zeta, optionally a domain conferring resistance to hypoxia.Figure 3: Examples of CD22 CAR constructs of the invention comprising a safety switch.At least a rituximab (R) mAb-specific epitopes (black box), preferably 3 rituximab mAb-specific epitopes and more preferably 3 rituximab mAb-specific epitopes and a QBEN-10 (Q) mAb-specific epitopes (grey box) are inserted into the CD22 CARR may be inserted into the scfv, between a VH and a VL domain (or a VL and a VH domain) and / or into the hinge.Figure 4: Example of a polypeptide coded by a polynucleotideFigure 4 represents one example of polypeptide which will be cleaved so that a safety switch (RQR8) and a CD22 CAR will be expressed at the cell surface.R=CD20 mimotope (bound by Rituximab), Q=CD34 epitope (bound by QBEnd10)Figure 5: Degranulating activity of UCART22Degranulating activity of UCART22 (scfv-V1 against the proximal domain of CD22) as compared to the degranulating activity of non transduced (NT) or that of T cells transduced with a CAR targeting the distal part of CD22 (scfv-V2), in the presence of CD22-positive NALM-16 cells as compared to CD22 negative SUP-T1 cells.Figure 6: Cytotoxic activity of UCART22Cytotoxic activity of UCART22 (scfv-V1 against the proximal domain of CD22) as compared to the cytotoxic activity of non transduced (NT) or that of T cells transduced with a CAR targeting the distal part of CD22 (scfv-V2) cells in the presence of CD22-positive NALM-16 cells as compared to CD22 negative SUP-T1 cells.Figure 7: Interferon gamma production of UCART22Figure 8: Mice survival in the presence of control cells, UCART22 (scfv-V1 against the proximal domain of CD22) or CART22 (no TRAC deletion).Figure 9: General Strategy to insert a gene into the TRAC gene using TALEN.Detailed description of the inventionUnless specifically defined herein, all technical and scientific terms used have the same meaning as commonly understood by a skilled artisan in the fields of gene therapy, biochemistry, genetics, immunology and molecular biology.All methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, with suitable methods and materials being described herein. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will prevail. Further, the materials, methods, and examples are illustrative only and are not intended to be limiting, unless otherwise specified.The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Current Protocols in Molecular Biology (Frederick M. AUSUBEL, 2000, Wiley and son Inc, Library of Congress, USA); Molecular Cloning: A Laboratory Manual, Third Edition, (Sambrook et a I, 2001, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D. Harries & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the series, Methods In ENZYMOLOGY (J. Abelson and M. Simon, eds. -in-chief, Academic Press, Inc., New York), specifically, Vols.154 and 155 (Wu et al. eds.) and Vol. 185, "Gene Expression Technology" (D. Goeddel, ed.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); and Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).CD22 specific Chimeric Antigen ReceptorsThe present invention relates to new designs of anti-CD22 chimeric antigen receptor (CAR or CD22 CAR or anti-CD22 CAR) which are chimeric antigen receptor capable of binding to CD22 in particular to the proximal domain of CD22.The CD22 specific Chimeric Antigen Receptors of the invention comprises an extracellular domain comprising an extracellular ligand-binding domain and a hinge, optionally a suicide domain, a transmembrane domain and an intracellular domain comprising a signaling transducing domain.Expressed at a cell surface, a CD22 CAR according to the present invention comprises an extracellular domain that comprises an extracellular ligand-binding domain.The term "extracellular ligand-binding domain" as used herein is defined as an oligo- or polypeptide that is capable of binding at least one epitope of CD22. Preferably, the extracellular ligand-binding domain will be capable of interacting at least partially with a cell surface molecule interacting with CD22 and with another cell surface antigen or another membrane bound antigen, or of interacting directly with CD22, or of interacting with human CD22, more precisely of interacting directly with the proximal region of human CD22 (from amino acid 243 to amino acid 687).In one embodiment, a CD22 CAR according to the present invention comprises an extracellular domain that comprises an extracellular ligand-binding domain capable of interacting with the proximal region of CD22 (from amino acid 243 to amino acid 687) and with the distal part of CD22 (from aa 20 to aa 425).In the present invention, the full length extracellular domain of CD22 is from amino acid (aa) 20-to aa 687, the membrane proximal domain of CD22 is from aa 243 to aa 687, the membrane distal domain of CD22 is from aa 20 to aa 425.In one embodiment, the extracellular ligand-binding domain may be chosen to recognize a particular form (glycosylated) CD22 that acts as a cell surface marker on target cells associated with a particular disease state.In a preferred embodiment, said extracellular ligand-binding domain comprises at least one single chain antibody fragment (scFv) comprising the light (VL) and the heavy (VH) variable fragment of a target antigen specific monoclonal anti CD22 antibody joined by a linker, in particular a flexible linker. Said VLand VH are preferably from the antibody m971 as in Table 2 below. They are preferably linked together by a flexible linker comprising for instance the sequence SEQ ID NO.10.For the purpose of the present invention, specific parts of the fully human anti-CD22 antibody, m971 antibody (m971) previously identified using phage display methodology and characterized. (Xiao X, Ho M, Zhu Z, Pastan I, Dimitrov DS. Identification and characterization of fully human anti-CD22 monoclonal antibodies. mAbs. 2009;1(3):297-303) were combined to specific sequences to produce new CD22 CARs, according to the invention. See also WO 2014065961 which is incorporated by reference.A preferred embodiment of the invention provides CARs comprising an antigen-binding domain comprising, consisting of, or consisting essentially of, a single chain variable fragment (scFv) of the antigen binding domain of m971 with the following moieties as in table 1Table 1: Sequence of different domains in CD22 CARTable 2: Sequence of the different CD22 scfv VH and VLTable 3: CD22 CAR of structure V-1Table 4: CAR of structure V-3In a preferred embodiment, the CD22 CAR of the invention comprises a sequence of SEQ ID N°15.In a preferred embodiment, the CD22 CAR of the invention comprises a sequence of SEQ ID N°23.Sequences of CD22 CARs of the invention comprise a peptide signal, a TM domain from CD8alpha and a linker between the VH and VL domain from m971.SCFVIn the present invention, a scfv is a fusion protein of the variable region of the heavy (VH domain) and light chain (VL domain) of an immunoglobulin or a part of an immunoglobulin specific for CD22, connected with a short linker peptide of 10 to 25 amino acids, preferably of SEQ ID NO. 10.In a preferred embodiment, said CARs preferentially comprise an extracellular ligand-binding domain comprising a polypeptide sequence displaying at least 90 %, 95 %, 96%, 97 %, 98%, 99 % or 100% identity with an amino acid sequence SEQ ID NO: 12.In a preferred embodiment, said CARs preferentially comprise an extracellular ligand-binding domain comprising a polypeptide sequence displaying at least 90 %, 95 %, 96%, 97 %, 98%, 99 % or 100% identity with an amino acid sequence SEQ ID NO: 13.In a preferred embodiment, said CARs preferentially comprise an extracellular ligand-binding domain comprising a polypeptide sequence displaying at least 90 %, 95 %, 96%, 97 %, 98%, 99 % or 100% identity with an amino acid sequence SEQ ID NO: 12.and a polypeptide sequence displaying at least 90 %, 91%, 92% 93% 94%, 95 %, 96%, 97 %, 98%, 99 % or 100% identity with an amino acid sequence selected from the group consisting of SEQ ID NO: 13.HINGEThe extracellular domain can further comprise a hinge region between said extracellular ligand-binding domain and said transmembrane domain. The term "hinge region" used herein generally means any oligo- or polypeptide that functions to link the transmembrane domain to the extracellular ligand-binding domain. In particular, hinge region is used to provide more flexibility and accessibility for the extracellular ligand-binding domain. A hinge region may comprise up to 300 amino acids, preferably 10 to 100 amino acids and most preferably 10 to 50 amino acids. Hinge region may be derived from all or part of naturally occurring molecules, such as from all or part of the extracellular region of CD8, or CD4, or from all or part of an antibody constant region. Alternatively the hinge region may be a synthetic sequence that corresponds to a naturally occurring hinge sequence, or may be an entirely synthetic hinge sequence. In a preferred embodiment said hinge domain comprises a part of a human CD8 alpha chain, FcRllla receptor or IgG1, respectively referred to in this specification as SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO.6, or in a more preferred embodiment, a hinge polypeptide which display at least 80%, preferably at least 90 %, 95 % 97 % 99 % or 100% sequence identity with SEQ ID N°4, even more preferably 100% sequence identity with SEQ ID N°4.A Hinge from lgG4 or from PD1 is part of the present invention and disclosed in WO2016120216 and may be used in the construction of a CD22 CAR according to the invention.A CD22 CAR according to the present invention is anchored into the membrane of the cell. Thus, such CD22 CAR further comprises a transmembrane domain. The distinguishing features of appropriate transmembrane domains comprise the ability to be expressed at the surface of a cell, preferably in the present invention an immune cell, in particular lymphocyte cells or Natural killer (NK) cells, and to interact together for directing cellular response of immune cell against a predefined target cell. The transmembrane domain can be derived either from a natural or from a syntheticsource. The transmembrane domain can be derived from any membrane-bound or transmembrane protein. As non-limiting examples, the transmembrane polypeptide can be a subunit of the T-cell receptor such as α, β, or δ, polypeptide constituting CD3 complex, IL2 receptor p55 (α chain), p75 (β chain) or chain, subunit chain of Fc receptors, in particular Fc receptor III or CD proteins. Alternatively, the transmembrane domain can be synthetic and can comprise predominantly hydrophobic residues such as leucine and valine.In a preferred embodiment said transmembrane domain is derived from the human CD8 alpha chain (e.g. NP_001139345.1).A CD22CAR according to the invention generally further comprises a transmembrane domain (TM) more particularly from CD8α, showing identity with the polypeptides of SEQ ID NO. 6 or SEQ. ID NO.7. Preferably, a CAR according to the invention comprises a TM showing at least 70%, preferably at least 80%, more preferably at least 90 %, 91%, 92%, 93%, 94%, 95 %, 96%, 97 %, 98%, 99 % or 100% sequence identity with the polypeptides of SEQ ID NO. 6.A CD22 CAR according to the invention generally further comprises a transmembrane domain (TM) from CD8α showing identity with the polypeptides of SEQ ID NO. 6. Preferably, a CAR according to the invention comprises a TM showing at least 70%, preferably at least 80%, more preferably at least 90 %, 91%, 92%, 93%, 94%, 95 %, 96%, 97 %, 98%, 99 % or 100% sequence identity with the polypeptides of SEQ ID NO. 6.A CD22 CAR according to the present invention comprises an intracellular domain that comprises a signal transducing domain or intracellular signaling domain.The signal transducing domain or intracellular signaling domain of a CD22 CAR according to the present invention is responsible for intracellular signaling following the binding of extracellular ligand binding domain to the target resulting in the activation of the immune cell and immune response (cytolytic activity against the target cell). In other words, the signal transducing domain is responsible for the activation of at least one of the normal effector functions of the immune cell in which the CAR is expressed. For example, the effector function of a T cell can be a cytolytic activity or helper activity including the secretion of cytokines. Thus, the term "signal transducing domain" refers to the portion of a protein which transduces the effector signal function signal and directs the cell to perform a specialized function.Preferred examples of signal transducing domain in a CD22 CAR of the invention can be the cytoplasmic sequences of the T cell receptor and co-receptors that act in concert to initiate signal transduction following antigen receptor engagement, as well as any derivate or variant of these sequences and any synthetic sequence that has the same functional capability. Signal transduction domain comprises two distinct classes of cytoplasmic signaling sequence, those that initiate antigen-dependent primary activation, and those that act in an antigen-independent manner to provide a secondary or co-stimulatory signal. Primary cytoplasmic signaling sequence can comprise signaling motifs which are known as immunoreceptor tyrosine-based activation motifs of ITAMs. ITAMs are well defined signaling motifs found in the intracytoplasmic tail of a variety of receptors that serve as binding sites for syk / zap70 class tyrosine kinases. Examples of ITAM used in the invention can include as non-limiting examples those derived from TCRzeta, FcRgamma, FcRbeta, FcRepsilon, CD3gamma, CD3delta, CD3epsilon, CD5, CD22, CD79a, CD79b and CD66d. In a preferred embodiment, the signaling transducing domain of the CAR can comprise the CD3zeta signaling domain which has amino acid sequence with at least 70%, preferably at least 80%, more preferably at least 90 %, 95 % 97 % 99 % or 100% sequence identity with amino acid sequence selected from the group consisting of (SEO ID NO: 9). Optionally said CD3zeta signaling domain is comprising a polypeptide sequence displaying at least 90 %, 91%, 92% 93% 94%, 95 %, 96%, 97 %, 98%, 99 % or 100% identity with SEO ID NO: 9.In a more preferred embodiment, the signaling transducing domain of the CD22 CAR consists in a CD3zeta signaling domain of SEO ID NO: 9 and excludes any sequence from human CD28 signaling domain. In particular embodiment the signal transduction domain of the CAR of the present invention comprises a co-stimulatory signal molecule. A co-stimulatory molecule is a cell surface molecule other than an antigen receptor or their ligands that is required for an efficient immune response. "Co-stimulatory ligand" refers to a molecule on an antigen presenting cell that specifically binds a cognate co-stimulatory molecule on a T-cell, thereby providing a signal which, in addition to the primary signal provided by, for instance, binding of a TCR / CD3 complex with an MHCmolecule loaded with peptide, mediates a T cell response, including, but not limited to, proliferation activation, differentiation and the like. A co-stimulatory ligand can include but is not limited to CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, inducible costimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM, CD30L, CD40, CD70, CD83, HLA-G, MICA, M1CB, HVEM, lymphotoxin beta receptor, 3 / TR6, ILT3, ILT4, an agonist or antibody that binds Toll ligand receptor and a ligand that specifically binds with B7-H3. A co-stimulatory ligand also encompasses, inter alia, an antibody that specifically binds with a co-stimulatory molecule present on a T cell, such as but not limited to, CD27, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LTGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83.A "co-stimulatory molecule" refers to the cognate binding partner on a T-cell that specifically binds with a co-stimulatory ligand, thereby mediating a co-stimulatory response by the cell, such as, but not limited to proliferation. Co-stimulatory molecules include, but are not limited to, an MHC class I molecule, BTLA and Toll ligand receptor. Examples of costimulatory molecules include CD27, CD8, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3 and a ligand that specifically binds with CD83 and the like.In a preferred embodiment, the signal transduction domain of the CAR of the present invention comprises a part of co-stimulatory signal molecule consisting of fragment of 4-1BB (GenBank: AAA53133.) In particular the signal transduction domain of the CAR of the present invention comprises amino acid sequence which comprises at least 70%, preferably at least 80%, more preferably at least 90 %, 95 % 97 % 99 % or 100% sequence identity with amino acid sequence selected from the group consisting of SEQ ID NO: 8.In a more preferred embodiment, the signal transduction domain of the CAR of the present invention comprises no sequence from CD28 (NP_006130.1).In an even more preferred embodiment, all the embodiments of the present invention comprise no sequence from CD28 (NP_006130.1).In an even more preferred embodiment the signal transduction domain of the CD22 CAR of the present invention comprises a part of co-stimulatory signal molecule 4-1BB (GenBank: AAA53133) and no sequence from CD28 (NP_006130.1).The present invention provides a CD22 specific chimeric antigen receptor (CD22 CAR) comprising:An extracellular domain comprising :- a binding domain specific for CD22, preferably a binding domain specific for human CD22, more preferably said binding domain specific for human CD22 is a single-chain variable fragment (scFv),- a hinge, preferably from CD8 alpha- a transmembrane domain, preferably from CD8 alpha- an intracellular domain comprising:- a co-stimulatory signal molecule from human 4-1BB, andan intracellular signaling domain comprising a human CD3zeta signaling domain.In a preferred embodiment the CD22 CAR of the invention has no sequence from CD28.In a preferred embodiment, the CD22 CAR of the invention does not contain any sequence from CD28 and comprises a sequence leader, a TM domain and a hinge from CD8 α, preferably no sequence from CD28 and comprises a sequence leader of SEQ ID NO. 1, a TM domain of SEQ ID NO. 6 of and a hinge of SEQ ID NO. 4 from CD8 α.In one embodiment, the CD22 CAR of the invention comprises a leader sequence from human CD8 α (SEQ ID NO.1.) or a leader sequence having at least 95% identity with SEQ ID NO.1.In another embodiment, The CD22 CAR of the invention comprises a leader sequence of SEQ ID NO.2 or a leader sequence having at least 95% identity with SEQ ID NO.2.In one embodiment the present invention provides a CD22 specific chimeric antigen receptor (CD22 CAR) comprising:- a binding domain specific for CD22, preferably a binding domain specific for human CD22, more preferably said domain specific for human CD22 is a single-chain variable fragment (scFv), even more preferably comprising a VH and an VL from m971,- a hinge from human CD8 alpha (from CD8 α)- a transmembrane domain from human CD8alpha(α)- a co-stimulatory signal molecule from human 4-1BB-an intracellular signaling domain comprising a human CD3zeta signaling domain.In one embodiment the present invention provides a CD22 specific chimeric antigen receptor (CD22 CAR) comprising:- a binding domain specific for CD22, preferably a binding domain specific for human CD22, more preferably said domain specific for human CD22 is a single-chain variable fragment (scFv), even more preferably comprising a VH and an VL from m971,- a hinge from human FcRIIIα- a transmembrane domain from human CD8alpha(α)- a co-stimulatory signal molecule from human 4-1BB-an intracellular signaling domain comprising a human CD3zeta signaling domain.The present invention also provides a CD22 specific chimeric antigen receptor (CD22 CAR) comprising:- a binding domain specific for CD22, preferably a binding domain specific for human CD22, more preferably said domain specific for human CD22 is a single-chain variable fragment (scFv), even more preferably comprising a VH and an VL from m971.- a hinge from human IgG1- a transmembrane domain from human CD8alpha(α)- a co-stimulatory signal molecule from human 4-1BB-an intracellular signaling domain comprising a human CD3zeta signaling domain.These three last embodiments encompass a CD22 CAR with a signal peptide of SEQ ID NO 1or of SEQ ID NO 2, preferably of SEQ ID NO 1More preferably, said CD22 CAR has no sequence from CD28.A scfv of the invention is derived from an antibody specific for CD22, it comprises a VH domain separated to a VL domain by a linker, said VH and / or VL domains contributing to the binding to CD22.In a preferred embodiment the UCART 22 of the invention comprises a scfv from m971 antibody with one GS4 linker between the VH and the VL and 2R between the VL and the CD8alpha hinge.In the present invention, a scfv is a fusion protein of the variable regions of the heavy (VH domain ) of SEO ID NO.12: and light chains (VL domain ) of SEO ID NO.13: of an immunoglobulin specific for CD22, m971, connected with a linker peptide, preferably a linker of SEO ID NO10.In one embodiment said scfv of the invention further comprises a leader sequence (or signal peptide), preferably said leader sequence is linked to the VH domain.An embodiment wherein said leader sequence is linked to the VL domain is part of the present invention.In one embodiment, a VH domain is linked to a hinge, in another embodiment a VL domain is linked to said hinge.The present invention provides a scfv linked to a hinge having different length preferably a hinge from CD8α, IgG1 or FcRIIIα (See figure 2), more preferably from CD8α.Preferably, the present invention provides a CD22 CAR comprising:- a signal peptide, for example a signal peptide of SEO ID NO. 2 or from CD8alpha of SEQ ID NO. 1.- a (scFv) comprising a VH domain separated from a VL domain by a linker, said VH and VL and linker contributing to the binding to CD22,- a hinge from human CD8 alpha chain or a Hinge from human IgG1 or a hinge from FcRIIIα, preferably from CD8 alpha.- a transmembrane domain (TM) from CD8alpha(α)- a co-stimulatory signal molecule from human 4-1BB- an intracellular signaling domain comprising the CD3zeta signaling domain.One of the CD22 CAR of the invention consists in :- a leader sequence (for example a CD8 α leader sequence or a CD8α signal peptide)- an anti-CD22 scfv comprising a VH, a linker, and a VL, or a VL, a linker, and a VH, said VH and VL are derived from m971• a CD8 α hinge• a CD8 α TM• a co-stimulatory signal molecule from 4-1BB• an intracellular CD3zeta signaling domain.One of the CD22 CAR of the invention comprises successively :- a CD8α signal peptide, removable upon expression at the cell surface,-an epitope recognized by QBEN10 and an epitope recognized by rituximab,- an anti-CD22 scfv comprising a VH, a linker, and a VL, said VH and VL from m971 two successive epitopes recognized by rituximab,• a CD8 α hinge• a CD8 α TM• a co-stimulatory signal molecule from 4-1BB• an intracellular CD3zeta signaling domainOne of the CD22 CAR of the invention comprises successively :- a CD8α signal peptide, removable upon expression at the cell surface,- an epitope recognized by QBEN10 and an epitope recognized by rituximab,- an anti-CD22 scfv comprising a VH, a linker, and a VL, said VH and VL from m971 two successive epitopes recognized by rituximab,• a CD8 α TM• a co-stimulatory signal molecule from 4-1BB• an intracellular CD3zeta signaling domainOne of the CD22 CAR of the invention comprises successively :- a CD8α signal peptide, removable upon expression at the cell surface,- an anti-CD22 scfv comprising a VH, a linker, and a VL, said VH and VL from m971 two successive epitopes recognized by rituximab,• a CD8 α hinge• a CD8 α TM• a co-stimulatory signal molecule from 4-1BB• an intracellular CD3zeta signaling domainOne of the CD22 CAR of the invention comprises successively :- a CD8α signal peptide, removable upon expression at the cell surface,- an anti-CD22 scfv comprising a VH, a linker, and a VL, said VH and VL from m971 two successive epitopes recognized by rituximab,• a CD8 α TM• a co-stimulatory signal molecule from 4-1BB• an intracellular CD3zeta signaling domainOne of the CD22 CAR of the invention comprises successively :- a CD8α signal peptide, removable upon expression at the cell surface,- an anti-CD22 scfv comprising a VH, a linker, and a VL, said VH and VL from m971, a anti-CD19 scfvtwo successive epitopes recognized by rituximab,• a CD8 α hinge• a CD8 α TM• a co-stimulatory signal molecule from 4-1BB• an intracellular CD3zeta signaling domainOne of the CD22 CAR of the invention comprises successively :- a CD8α signal peptide, removable upon expression at the cell surface,- an anti-CD22 scfv comprising a VH, a linker, and a VL, said VH and VL from m971, an anti-CD19 scfvtwo successive epitopes recognized by rituximab,• a CD8 a TM• a co-stimulatory signal molecule from 4-1BB• an intracellular CD3zeta signaling domainOne of the CD22 CAR of the invention comprises successively :- a CD8α signal peptide, removable upon expression at the cell surface,- an anti-CD19 scfv and an anti-CD22 scfv comprising a VH, a linker, and a VL, said VH and VL from m971,two successive epitopes recognized by rituximab,• a CD8 α hinge• a CD8 a TM• a co-stimulatory signal molecule from 4-1BB• an intracellular CD3zeta signaling domainOne of the CD22 CAR of the invention comprises successively :- a CD8α signal peptide, removable upon expression at the cell surface,- an anti-CD19 scfv and an anti-CD22 scfv comprising a VH, a linker, and a VL, said VH and VL from m971,two successive epitopes recognized by rituximab,• a CD8 a TM• a co-stimulatory signal molecule from 4-1BB• an intracellular CD3zeta signaling domain.LINKER -SCFVA linker according to the invention may be for example, a multimer of the pentapeptide (GGGGS)n or (G4S)n or (Gly4Ser)n with n= 1 to 4, preferably n=3 , the 18-mer GGSSRSSSSGGGGSGGGG (Andris-Widhopf et al., 2011) and the 20-mer (G4S)4 (Schaefer et al., 2010). A linker according to the invention may include sequences with added functionalities, e.g. an epitope tag (Sblattero & Bradbury, 2000 Nature Biotechnology 18, 75 - 80), at least on sequence of SEQ ID NO. 20, preferably 2, separated by a linker, sequences improving scFv properties of the present invention, often in the context of particular antibody sequences.Amongst other linkers suitable within the present invention is the 15-mer peptide linker (RGRGRGRGRSRGGGS) (Zhihong Shen, Heping Yan, Ying Zhang, Raymond L. Mernaugh, and Xiangqun Zeng (2008), Anal Chem. 80(6): 1910-1917).In a preferred embodiment, a linker linking the VH to the VL sequence of m971 (or the VL to the VH sequence) is a linker of formula (G4S)n wherein n is 1 to 3; preferably n=3 of sequence (G4S)3 ( SEQ ID NO. 10).In one embodiment the present invention provides:A CD22 CAR comprising- a human CD8α leader sequence (CD8 α leader or CD8α signal peptide) of SEQ ID NO. 1- an anti-CD22 scfv comprising a VH of SEQ ID NO. 12, a linker of SEQ ID N°10, and a VL of SEQ ID NO 13a human CD8 α hinge of SEQ ID NO.4,• a human CD8 α TM of SEQ ID NO.6• a co-stimulatory signal molecule from 4-1BB of SEQ ID NO.8• an intracellular CD3zeta signaling domain of SEQ ID NO. 9.In one embodiment the present invention also provides:A CD22 CAR comprising- a human CD8α leader sequence (CD8 a leader or CD8α signal peptide) of SEQ ID NO. 1- an anti-CD22 scfv comprising a VH of SEQ ID NO. 12, a linker of SEQ ID N°10, and a VL of SEQ ID NO 13a human FcγRIIIα hinge of SEQ ID NO.3,• a human CD8 α TM of SEQ ID NO.6• a co-stimulatory signal molecule from 4-1BB of SEQ ID NO.8• an intracellular CD3zeta signaling domain of SEQ ID NO. 9.In one embodiment, the present invention providesAn CD22 CAR comprising- a human CD8α leader sequence (CD8 α leader or CD8α signal peptide) of SEQ ID NO. 1 an anti-CD22 scfv comprising a VL of SEQ ID NO 13, a linker of SEQ ID N°10, and a VH of SEQ ID NO. 12,a human FcγRIIIα hinge of SEQ ID NO.3,• a human CD8 α TM of SEQ ID NO.6• a co-stimulatory signal molecule from 4-1BB of SEQ ID NO.8• an intracellular CD3zeta signaling domain of SEQ ID NO. 9.In one embodiment, the present invention providesAn CD22 CAR comprising- a human CD8α leader sequence (CD8 α leader or CD8α signal peptide) of SEQ ID NO. 1 an anti-CD22 scfv comprising a VL of SEQ ID NO 13, a linker of SEQ ID N°10, and a VH of SEQ ID NO. 12,a human CDA alpha hinge of SEQ ID NO.4,• a human CD8 α TM of SEQ ID NO.6• a co-stimulatory signal molecule from 4-1BB of SEQ ID NO.8• an intracellular CD3zeta signaling domain of SEQ ID NO. 9.In one embodiment, the present invention provides a CD22 specific chimeric antigen receptor (CD22 CAR) comprising:- a signal peptide having an amino acid sequence with at least 80%, more preferably at least 90 %, 95 % 97 %, 99 % or 100% sequence identity with the polypeptide of SEQ ID NO. 1 or 2; preferably the signal peptide has an amino acid sequence with at least 80%, more preferably at least 90 %, 95 % 97 %, 99 % or 100% sequence identity with the polypeptide of SEQ ID NO 1.- a VH domain separated to a VL domain by a linker, said VH and VL contributing to the binding to CD22; said linker having at least 90 %, 95 % 97 %, 99 % or 100% sequence identity with the polypeptide of SEQ ID NO 10.Said VH domain having at least 90 %, 95 % 97 %, 99 % or 100% sequence identity with the polypeptide of SEQ ID NO 12.Said VL domain having at least 90 %, 95 % 97 %, 99 % or 100% sequence identity with the polypeptide of SEQ ID NO 13.- - a hinge derived from human CD8 alpha chain having an amino acid sequence with at least 80%, more preferably at least 80%, 90 %, 95 % 97 %, 99 % or 100% sequence identity with the polypeptide of SEQ ID NO. 4.- a transmembrane domain derived from CD8alpha(a) having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the polypeptide of SEQ ID NO. 6;- a co-stimulatory signal molecule derived from human 4-1BB (or 4-1BB intracellular domain) having an amino acid sequence with at least 70%, preferably at least 80%, more preferably at least 90 %, 95 % 97 %, 99 % or 100% sequence identity with amino acid sequence selected from the group consisting of SEQ ID NO: 8-an intracellular signaling domain comprising the CD3zeta signaling domain having an amino acid sequence with at least 70%, preferably at least 80%, more preferably at least 90%, 95% 97%, 99 % or 100 % sequence identity with amino acid sequence selected from the group consisting of SEQ ID NO: 9.In a preferred embodiment, the CD22 specific chimeric antigen receptor (CD22 CAR) of the present invention does not comprise any sequence from human CD28, in particular from human CD28 intra signaling domain. In a more preferred embodiment, the CD22 specific chimeric antigen receptor (CD22 CAR) of the present invention does not comprise any sequence from human CD28, in particular from human CD28 intra signaling domain and further contains a signal peptide from CD8a, preferably fused to the VH domain of a scfv specific for CD22.In one embodiment, the present invention provides a CD22 CAR of SEQ ID NO. 15.In one embodiment, the present invention provides a CD22 CAR having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the polypeptide of SEQ ID N°15.In one embodiment the present invention provides a CD22 CAR having a sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the polynucleotide of SEQ ID N°22.The CD22 CAR of the invention encompasses the following sequences:v1-m971 (FcγRIIIα-CD8αTM-41BB.IC-.IC)N°14).V3-m971 (CD8α-CD8αTM-41BB.IC-.IC)In a preferred embodiment the CD22 CAR of the invention comprises the following sequence.Sequences of CD22 CAR with a peptide signal from SEQ ID NO.2, a TM domain from CD8α and a linker between the VH and VL domain :M971 V1M971 V3In one embodiment the present invention provides the following sequences:ALPPR. In this CD22CAR the signal peptide is absent.In one embodiment, the UCART22 of the present invention comprises a sequence of SEQ ID N° 20In one embodiment, the UCART22 of the present invention comprises a sequence of SEQ ID N° 22In a preferred embodiment the UCART22 of the present invention comprises a sequence of SEQ ID N° 22 inserted into a human TRAC gene (such as in human TRAC geneChromosome 14 - NC_000014.9) and expresses at the cell surface an anti-CD22 CAR specific for the proximal part of CD22.In a more preferred embodiment the UCART22 of the present invention comprises a sequence of SEQ ID N° 20 inserted into a human TRAC gene (such as in human TRAC gene Chromosome 14 - NC_000014.9) and expresses at the cell surface an anti-CD22 CAR specific for the distal part of CD22.In one aspect, an anti-CD22 binding domain of the CD22 CAR of the invention is an anti- CD22 binding domain specific for the distal portion of CD22.HA22-CARAccordingly the present invention provides a CD22 CAR with the following sequence :Preferably the UCART22 of the present invention comprises a sequence :An anti- CD22 binding domain specific for the distal portion of CD22 may be expressed alone or with an anti- CD22 binding domain specific for the proximal portion of CD22 in the UCART22 of the invention.In one aspect, the anti-CD22 binding domain of the CD22 CAR of the invention is an optimized anti- CD22 binding domain.As used herein, "optimized" antibody (or scfv) refers to forms of antibodies (or scfv) that are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen binding subsequences of antibodies) that contain minimal sequences derived from immunoglobulin. Preferably, antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) are replaced by residues from a CDR to achieve the desired specificity, affinity, and capacity.The donor CDR may undergo few amino acid changes that may significantly affect or alter the binding characteristics of the CD22 CAR of the invention. Indeed, one of the invention provided here is a CD22 CAR which binding to CD22-expressing cell (and cytolytic activity) is maintained but the affinity is modified to reduce the intensity of the response (cytokine release).Amino acid modifications are usually conservative modifications including amino acid substitutions, additions and deletions in said antibody fragment in said CAR and / or any of the other parts of said CAR molecule. Modifications can be introduced into an antibody, into an antibody fragment or in any of the other parts of the CAR molecule of the invention by standard techniques known in the art, such as site-directed mutagenesis, PCR-mediated mutagenesis or by employing optimized germline sequences.In general, the optimized CAR will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to the original human immunoglobulin.Conservative amino acid substitutions mean substitutions in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains(e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within a CAR of the invention can be replaced with other amino acid residues from the same side chain family and the altered CAR can be tested using the functional assays described herein.In a preferred embodiment, the present invention provides a CD22 CAR having conservative sequence modifications (or an amino acid sequence change) as compared to the amino acid sequence of the polypeptide of SEQ ID N°15.In a preferred embodiment, the present invention provides a CD22 CAR having an amino acid sequence with 2 amino acid changes as compared to the amino acid sequence of the polypeptide of SEQ ID N°15.In a preferred embodiment, the present invention provides a CD22 CAR having an amino acid sequence with 3 amino acid changes as compared to the amino acid sequence of the polypeptide of SEQ ID N°15.In a preferred embodiment, the present invention provides a CD22 CAR having an amino acid sequence with 4 amino acid changes as compared to the amino acid sequence of the polypeptide of SEQ ID N°15In a preferred embodiment, the present invention provides a CD22 CAR having an amino acid sequence with 5 amino acid changes as compared to the amino acid sequence of the polypeptide of SEQ ID N°15, optionally comprising at least one sequence of SEQ ID NO 20.In a more preferred embodiment, the present invention provides a CD22 CAR having an amino acid sequence with 5 amino acid changes as compared to the amino acid sequence of the polypeptide of SEQ ID N°15 and at least one CDR in SEQ ID N°15 is conserved.In a more preferred embodiment, the present invention provides a CD22 CAR having an amino acid sequence with from 1 to 15 amino acid changes as compared to the amino acid sequence of the polypeptide of SEQ ID N°15 and at least one CDR in SEQ ID N°15,is conserved.In a preferred embodiment, the sequence of CD22 CAR of the invention is modified by changing 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids as compared to the wt CD22 CAR, to reduce the HAMA (human anti-mouse response), without affecting the binding capacity of said CAR to its target (CD22).In a preferred embodiment, the present invention provides a CD22 CAR having an amino acid sequence with at least 1 amino acid change as compared to the amino acid sequence of wt (wt is m971) said at least 1 amino acid change having no impact or improving the binding and / or activity of said CD22 CAR in primary T cells.Binding characteristics may be modified using adapted technique initially described in Mitchell Ho, Satoshi Nagata, and Ira Pastan. Isolation of anti-CD22 Fv with high affinity by Fv display on human cells PNAS 2006 103 (25) 9637-9642; published ahead of print June 8, 2006, doi:10.1073 / pnas.0603653103 which is incorporated herein by reference.Those optimized scfv also bear at least one mutations equivalent to mutations Pro-91-Thr-92 (PT) Gly-91-Ala-92 and Val-91-Phe-92.In one embodiment the present invention provides an anti CD22 CAR comprising :- An extracellular domain comprisinga signal peptidea ligand binding-domain optionally optimized comprising a VH domain and a VL domain from a monoclonal anti-CD22 antibody having one of the following Pro-91-Thr-92 (PT), Gly-91-Ala-92, Val-91-Phe-92, mutations or equivalent,a hinge, comprising a CD8 alpha (a) hinge- a CD8 alpha transmembrane domain and- a cytoplasmic domain comprising a CD3 zeta signaling domain and a co-stimulatory domain from 4-1BB.In a preferred embodiment the present invention provides an anti CD22 CAR as above wherein said monoclonal anti-CD22 antibody is from m971 antibody with hotsspot in CDRs. Preferably, one of the following Pro-91-Thr-92 (PT), Gly-91-Ala-92, Val-91-Phe-92, mutations.In a more preferred embodiment the present invention provides an isolated engineered (TCR and dCK KO) immune T cell comprising an anti CD22 CAR comprising• An extracellular domain comprising,a signal peptide, a ligand binding-domain comprising a VH domain and a VL domain from a monoclonal anti-CD22 antibody having at least one of the following Pro-91-Thr-92, Gly-91-Ala-92 mutation; Val-91-Phe-92 mutation,a hinge, comprising a CD8 alpha (α) hinge- a CD8 alpha transmembrane domain and- a cytoplasmic domain comprising a CD3 zeta signaling domain and a co-stimulatory domain from 4-1BB.In a more preferred embodiment the present invention provides an isolated engineered (TCR and CD52 KO) immune T cell comprising an anti CD22 CAR comprising• An extracellular domain comprising,a signal peptide, a ligand binding-domain comprising a VH domain and a VL domain from a monoclonal anti-CD22 antibody having at least one of the following Pro-91-Thr-92, Gly-91-Ala-92 mutation; Val-91-Phe-92 mutation,a hinge, comprising a CD8 alpha (α) hinge- a CD8 alpha transmembrane domain and- a cytoplasmic domain comprising a CD3 zeta signaling domain and a co-stimulatory domain from 4-1BB.In a more preferred embodiment the present invention provides an isolated engineered (TCR, CD52 and dCK KO) immune T cell comprising an anti CD22 CAR comprising• An extracellular domain comprising,a signal peptide, a ligand binding-domain comprising a VH domain and a VL domain from a monoclonal anti-CD22 antibody having at least one of the following Pro-91-Thr-92, Gly-91-Ala-92 mutation; Val-91-Phe-92 mutation,a hinge, comprising a CD8 alpha (a) hinge- a CD8 alpha transmembrane domain and- a cytoplasmic domain comprising a CD3 zeta signaling domain and a co-stimulatory domain from 4-1BB.In one aspect, the CAR 22 may be coexpressed at the cell surface with at least one, preferably two, more preferably three, monoclonal antibody (mAb)-specific epitopes, said mAb-specific epitope may be fused to a transmembrane domain of CD8. In one embodiment said mAb -specific epitope is an epitope recognized by rituximab, and / or from QBEN10 and the peptide coexpressed with the cD22 CAR is RQR8.In another embodiment, at least one, preferably two, more preferably three, monoclonal antibody (mAb)-specific epitopes, may be inserted into the linker L of the scfv (binding the VH to the VL) specific for CD22 and / or into the hinge of the CD22 CAR.Molecular antibody (mAb)-specific epitope, may be one of the following a mAb-specific epitope specifically recognized by an monoclonal antibody selected from ibritumomab, tiuxetan, muromonab-CD3, tositumomab, abciximab, basiliximab, brentuximab vedotin, cetuximab, infliximab, rituximab, alemtuzumab, bevacizumab, certolizumab pegol, daclizumab, eculizumab, efalizumab, gemtuzumab, natalizumab, omalizumab, palivizumab, ranibizumab, tocilizumab, trastuzumab, vedolizumab, adalimumab, belimumab, canakinumab, denosumab, golimumab, ipilimumab, ofatumumab, panitumumab, Q.BEND-10 and ustekinumab, preferably from rituximab (R) and / or fromQBEN10 (Q).The epitope-specific mAb may be used for in vitro cell sorting and / or in vivo cell depletion of immune cells expressing a CD22.In particular embodiments, the extracellular binding domain of the CD22 CAR of the invention may comprises one of the following sequences :V1-L1-V2-(L)x-Epitope1-(L)x-;V1-L1-V2-(L)x-Epitope1-(L)x-Epitope2-(L)x-;V1-L1-V2-(L)x-Epitope1-(L)x-Epitope2-(L)x-Epitope3-(L)x-;(L)x-Epitope1-(L)x-V1-L1-V2;(L)x-Epitope1-(L)x-Epitope2-(L)x-V1-L1-V2;Epitope1-(L)x-Epitope2-(L)x-Epitope3-(L)x-V1-L1-V2;(L)x-Epitope1-(L)x-V1-L1-V2-(L)x-Epitope2-(L)x;(L)x-Epitope1-(L)x-V1-L1-V2-(L)x-Epitope2-(L)x-Epitope3-(L)x-;(L)x-Epitope1-(L)x-V1-L1-V2-(L)x-Epitope2-(L)x-Epitope3-(L)x-Epitope4-(L)x-;(L)x-Epitope1-(L)x-Epitope2-(L)x-V1-L1-V2-(L)x-Epitope3-(L)x-;(L)x-Epitope1-(L)x-Epitope2-(L)x-V1-L1-V2-(L)x-Epitope3-(L)x-Epitope4-(L)x-;V1-(L)x-Epitope1-(L)x-V2;V1-(L)x-Epitope1-(L)x-V2-(L)x-Epitope2-(L)x;V1-(L)x-Epitope11(L)x-V2-(L)x-Epitope2-(L)x-Epitope3-(L)x;V1-(L)x-Epitope1-(L)x-V2-(L)x-Epitope2-(L)x-Epitope3-(L)x-Epitope4-(L)x;(L)x-Epitope1-(L)x-V1-(L)x-Epitope2-(L)x-V2;or,(L)x-Epitope1-(L)x-V1-(L)x-Epitope2-(L)x-V2-(L)x-Epitope3-(L)x;wherein,V1 is VL, preferably of SEQ ID N°12 and V2 is VH, preferably of SEQ ID N°13 or V1 is VH and V2 is VL;L1 is a linker suitable to link the VH chain to the VL chain; preferably of SEQ ID N°10L is a linker comprising glycine and serine residues, and each occurrence of L in the extracellular binding domain can be identical or different to other occurrence of L in the same extracellular binding domain, and,x is 0 or 1 and each occurrence of x is selected independently from the others; and,Epitope 1, Epitope 2 and Epitope 3 are mAb-specific epitopes and can be identical or different.In one embodiment, the extracellular binding domain comprises one of the following sequencesV1-L1-V2-L-Epitope1; V1-L1-V2-L-Epitope1-L; V1-L1-V2-L-Epitope1-L-Epitope2; V1-L1-V2-L-Epitope1-L-Epitope2-L; V1-L1-V2-L-Epitope1-L-Epitope2-L-Epitope3; V1-L1-V2-L-Epitope1- L-Epitope2-L-Epitope3-L; V1-L1-V2-Epitope1; V1-L1-V2-Epitope1-L; V1-L1-V2-Epitope1-L-Epitope2; V1-L1-V2-Epitope1-L-Epitope2-L; V1-L1-V2-Epitope1-L-Epitope2-L-Epitope3; V1-L1-V2-Epitope1-L-Epitope2-L-Epitope3-L; Epitope1-V1-L1-V2; Epitope1-L-V1-L1-V2; L-Epitope1-V1-L1-V2; L-Epitope1-L-V1-L1-V2; Epitope1-L-Epitope2-V1-L1-V2; Epitope1-L-Epitope2-L-V1-L1-V2; L-Epitope1-L-Epitope2-V1-L1-V2; L-Epitope1-L-Epitope2-L-V1-L1-V2; Epitope1-L-Epitope2-L-Epitope3-V1-L1-V2; Epitope1-L-Epitope2-L-Epitope3-L-V1-L1-V2; L-Epitope1-L-Epitope2-L-Epitope3-V1-L1-V2; L-Epitope1-L-Epitope2-L-Epitope3-L-V1-L1-V2;V1-L-Epitope1-L-V2; L-Epitope1-L-V1-L-Epitope2-L-V2; V1-L-Epitope1-L-V2-L-Epitope2-L; V1-L-Epitope1-L-V2-L-Epitope2-L-Epitope3; V1-L-Epitope1-L-V2-L-Epitope2-Epitope3; V1-L-Epitope1-L-V2-L-Epitope2-L-Epitope3-Epitope4; L-Epitope1-L-V1-L-Epitope2-L-V2-L-Epitope3-L; Epitope1-L-V1-L-Epitope2-L-V2-L-Epitope3-L; L-Epitope1-L-V1-L-Epitope2-L-V2-L-Epitope3; L-Epitope1-L-V1-L1-V2-L-Epitope2-L; L-Epitope1-L-V1-L1-V2-L-Epitope2-L-Epitope3; L-Epitope1-L-V1-L1-V2-L-Epitope2-Epitope3, or Epitope1-L-V1-L1-V2-L-Epitope2-L-Epitope3-Epitope4 whereinV1 is VL and V2 is VH or V1 is VH and V2 is VL; and VH, and VL are optimized VH and VL from m971.L1 is any linker suitable to link the VH chain to the VL chain;L is a linker comprising glycine and serine residues, and each occurrence of L in the extracellular binding domain can be identical or different to other occurrences of L in the same extracellular binding domain, and,Epitope 1, Epitope 2 and Epitope 3 are mAb-specific epitopes and can be identical or different.L1 is a linker comprising Glycine and / or Serine, preferably, L1 is a linker comprising the amino acid sequence (Gly-Gly-Gly-Ser)n or (Gly-Gly-Gly-Gly-Ser)n, where n is 1, 2, 3, 4 or5 or a linker comprising the amino acid sequence (Gly4Ser)4 or (Gly4Ser)3.Similarly, L is a linker comprising Glycine and / or Serine, preferably L is a linker having an amino acid sequence selected from SGG, GGS, SGGS, SSGGS, GGGG, SGGGG, GGGGS, SGGGGS, GGGGGS, SGGGGGS, SGGGGG, GSGGGGS, GGGGGGGS, SGGGGGGG, SGGGGGGGS, and SGGGGSGGGGS, preferably .L is a SGGGG, GGGGS or SGGGGS.In a preferred embodiment, Epitope 1, Epitope 2, Epitope 3 and Epitope 4 are independently selected from mAb-specific epitopes specifically recognized byibritumomab, tiuxetan, muromonab-CD3, tositumomab, abciximab, basiliximab, brentuximab vedotin, cetuximab, infliximab, rituximab, alemtuzumab, bevacizumab, certolizumab pegol, daclizumab, eculizumab, efalizumab, gemtuzumab, natalizumab, omalizumab, palivizumab, ranibizumab, tocilizumab, trastuzumab, vedolizumab, adalimumab, belimumab, canakinumab, denosumab, golimumab, ipilimumab, ofatumumab, panitumumab, Q.BEND-10 and ustekinumab, preferably Epitope 1, Epitope 2, Epitope 3 and Epitope 4 are recognized by rituximab or QBEND-10.Epitope 1, Epitope 2, Epitope 3 and Epitope 4 are mAb-specific epitopes specifically recognized by :The mAb-specific epitope may therefore comprise one polypeptide selected from :Antibody mAb-specific epitopeIn a preferred embodiment, the mAb-specific epitope is a mAb-specific epitope having an amino acid sequence of ELPTQGTFSNVSTNVSPAKPTTTA and / or CPYSNPSLC (SEQ ID NO19).In a more preferred embodiment, the CD22 CAR of the invention comprises 3 mAb- specific epitopes having an amino acid sequence of CPYSNPSLC (R) and one having an amino acid sequence of ELPTQGTFSNVSTNVSPAKPTTTA (Q).In an even more preferred embodiment, the CD22 CAR of the invention comprises 2 mAb-specific epitopes having an amino acid sequence of CPYSNPSLC (R) located at the NT part of the hinge, just after the VL.In one aspect, at least one sequence to which rituximab binds to (R) and / or a sequence to which QBEN10 binds to (Q) may be inserted into the linker GGGGSGGGGSGGGGS and / or into the Hinge as previously described in (WO2016120216).In a particular embodiment, the CD22 CAR of the present invention is a single chain CAR (scCAR).In particular embodiments, the single chain anti-CD22 CAR of the invention comprises a scfv from m971 and at least one other binding domain, preferably specific for the distal part of CD22, alternatively for another B cell antigen, especially if expressed by B cells malignancies such as CD34, CD10, CD79a, CD20, IgD, CD5, CD23, CD19, STAT5, CD3,CD30, BCMA.In a particular embodiment, the CD22 CAR of the present invention is a multichain CAR (mcCAR). Multichain CD22 CARs are part of the present invention and may be produced as described in details in WO2014039523, which is incorporated herein by reference. In a particular embodiment, the VH domain and the VL domain of an immunoglobulin or a part of an immunoglobulin specific for CD22, may be carried by two different and isolated (non covalently bound) chains of a multichain CAR.In a multichain version, the CD22 CAR of the invention comprises at least two, preferably 3 transmembrane domains (non covalently bound to each other) with at least one of the transmembrane domain comprising a scfv specific for CD22 of the invention.In a particular embodiment, the VH domain and the VL domain of an immunoglobulin specific for CD22, preferably from m971 may be carried by one chain of a multichain CAR.An example of sc CD22 CAR and of mc CD22 CAR of the invention is provided figure 2.In a particular embodiment, the VH domain and the VL domain of an immunoglobulin specific for CD22, preferably from m971 may be carried by one chain of a multichain CAR and the VH domain and the VL domain of another immunoglobulin specific for CD22, may be carried by another chain of the mc CAR.Downregulation or mutation of target antigens is commonly observed in cancer cells, creating antigen-loss escape variants. Thus, to offset tumor escape and render immune cell more specific to target, the CD22 specific CAR according to the invention can comprise another extracellular ligand-binding domain, to simultaneously bind other elements in target thereby augmenting immune cell activation and function. In one embodiment, the extracellular ligand-binding domains can be placed in tandem on the same transmembrane polypeptide, and optionally can be separated by a linker.In another embodiment, said different extracellular ligand-binding domains can be placed on different transmembrane polypeptides composing the multichain CAR. In another embodiment, the present invention relates to a population of CARs comprising different extracellular ligand binding domains, one of each is specific for CD22.In one embodiment the extracellular binding domain specific for CD22 and the second extracellular binding domain are on the same scCAR,In another embodiment, the extracellular binding domain specific for CD22 and the second extracellular binding domain are on the same mc CAR and belong to the same or to two different and non covalently bound transmembrane domains of said mc CAR.As other second extracellular binding domain may be any extracellular binding domain binding specific to an antigen associated (coexpressed - even temporarily) to CD22 on pathological cells, such as CD34, CD10, CD79a, CD20, IgD, CD5, CD23, CD19, STAT5, CD3, CD30, BCMA, PAX5,CD19, CD20, CD30, glycosphingolipids, a major histocompatibility complex (MHC) molecule, an Ig, CD3, CD34, CD79, preferably CD79a, CD138, B7-1 (CD80), B7-2 (CD86), a major histocompatibility complex (MHC) molecule, BCMA (CD269, TNFRSF 17) or FLT-3, Pax5.The invention also provides related CD22 CAR nucleic acids, CD22 CAR recombinant expression vectors, engineered TCR KO cells, preferably T cells comprising at least another edited gene endowed with the CD22 CAR, populations of said TCR KO cells endowed with a CD22 CAR, and pharmaceutical compositions relating to the CD22 CARs, protein, expression vector, engineered TCR KO CD52 KO cells expressing said CD22CAR of the invention.The invention provides the following objects : a CD22 CAR of the invention -related nucleic acids, -recombinant expression vectors, engineered TCR KO cells comprising at least another edited gene selected from a gene conferring resistance to hypoxia, a gene conferring resistance to alemtuzumab, to protease inhibitor, such as bortezomib, a gene conferring resistance to PNA (dCK) and endowed with a CD22 CAR, and related nucleic acid, populations of engineered TCR KO cells comprising at least another edited gene as below, endowed with said CD22 CAR and pharmaceutical compositions comprising said same objects as a medicament.Polynucleotides, vectors:The present invention relates to polynucleotides, vectors encoding the above described CD22 CAR according to the invention.A polynucleotide may consist in an expression cassette or expression vector (e.g. a plasmid for introduction into a bacterial host cell, or a viral vector such as a baculovirus vector for transfection of an insect host cell, or a plasmid or viral vector such as a lentivirus or an adeno associated virus for introduction into a mammalian, preferably human host cell.In a particular embodiment, the different nucleic acid sequences can be included in one polynucleotide or vector which comprises a nucleic acid sequence encoding ribosomal skip sequence such as a sequence encoding a 2A peptide. 2A peptides, which were identified in the Aphthovirus subgroup of picornaviruses, causes a ribosomal "skip" from one codon to the next without the formation of a peptide bond between the two amino acids encoded by the codons (see (Donnelly and Elliott 2001; Atkins, Wills et al.2007; Doronina, Wu et al. 2008)).Accordingly the present invention provides a vector as in figure 4 coding for a RQR8 and an anti-CD22CAR linked by a peptide 2A.By "codon" is meant three nucleotides on an mRNA (or on the sense strand of a DNA molecule) that are translated by a ribosome into one amino acid residue. Thus, two polypeptides can be synthesized from a single, contiguous open reading frame within an mRNA when the polypeptides are separated by a 2A oligopeptide sequence that is in frame. Such ribosomal skip mechanisms are well known in the art and are known to be used by several vectors for the expression of several proteins encoded by a single messenger RNA.A vector allowing a CD22 CAR of the invention to be expressed in a cell is another object of the present invention. In a preferred embodiment, said vector allows a transient expression of the CD22 CAR of the invention. In a more preferred embodiment said vector allows a constitutive and stable expression of a CD22 CAR of the invention by insertion of the sequence coding said CD22 CAR into the genome of a cell.The expression of a CD22 CAR of the invention and / or the survival of the cell expressing the CD22 CAR of the invention may be controlled using a gene under the control of an inducible promoter as described in (R. Kuhn, F. Schwenk, M. Aguet, K.Rajewsky. Inducible gene targeting in mice. Science 8 September 1995: Vol. 269 no.5229 pp. 1427-1429 DOI:10.1126 / science.7660125, and cited references.In one embodiment, a CD22 CAR is provided wherein the extracellular domain comprises at least two CD20 mimotopes of SEQ ID NO 19 (CPYSNPSLC) located between m971 scfv domains and the hinge from human CD8alpha. Document Patent WO2016120216A1 discloses a method for preparing such constructions and is incorporated herein by reference.In one embodiment, the present invention provides a vector comprising a sequence coding a CD22 CAR selected from SEQ ID NO. 22.To direct transmembrane polypeptide into the secretory pathway of a host cell, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) is provided in polynucleotide sequence or vector sequence. The secretory signal sequence is operably linked to the transmembrane nucleic acid sequence, i.e., the two sequences are joined in the correct reading frame and positioned to direct the newly synthesized polypeptide into the secretory pathway of the host cell. Secretory signal sequences are commonly positioned 5' to the nucleic acid sequence encoding the polypeptide of interest, although certain secretory signal sequences may be positioned elsewhere in the nucleic acid sequence of interest (see, e.g., Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830). In a preferred embodiment the signal peptide comprises the amino acid sequence SEQ ID NO: 1 and 2.
Claims
CLAIMS1. An engineered human T Cell Receptor Knock Out (TCR KO) cell endowed with a Chimeric Antigen Receptor (CAR) specific for CD22 (UCART 22), a safety switch, preferably expressed at the cell surface, said anti-CD22 CAR (CD22 CAR) comprising:i) at least one extracellular domain comprising :- a hinge domain from CD8alpha,- an antigen binding domain specific for CD22, optionally a leader sequence,ii) a transmembrane domain from CD8alpha, andiii) an intracellular signaling domain said CD22 CAR having a polypeptide sequence with at least 80% identity with SEQ ID N°15,said safety switch comprising :- a RQR8 temporarily linked to the CD22 CAR by a peptide 2A, or- at least two rituximab mAb-specific epitopes, preferably located between the VH and the Hinge domain, or 3 rituximab mAb-specific epitopes or 3 rituximab mAb-specific epitopes and a QBEN-10 mAb-specific epitopes linked to the CD22 CAR.
2. The UCART 22 of claim 1 wherein a polynucleotide sequence having at least 80% identity with SEQ ID N°11 is inserted into the genome, and further comprising an inactivated TRAC gene with an insertion, a deletion or a mutation within SEQ ID N°18, withundetectable level of T Cell Receptor (TCR) at the cell surface as measured by flow cytometry, and undetectable level of off site events as measured by guide sequence technique.
3. The UCART22 according to claim 2 wherein said anti-CD22 CAR is inserted preferably into the TRAC gene, preferably with SEQ ID N°18.
4. The UCART22 according to any one of claim 1 to 2 comprising another inactivated gene selected from dCK gene, B2M gene, CD52 gene, preferably CD52 gene.
5. The UCART22 according to any one of claim 1 to 4 wherein and at least one additional gene is inactivated, said gene is selected from a gene encoding aryl hydrocarbon receptor (AHR), Transforming growth factor beta receptor) (TGF beta receptor), Interleukin 10 receptor (IL-10 R), Program cell death protein 1, a combination thereof.
6. The UCART22 according to any one of claim 1 to 5 comprising an additional scfv specific for any one of the following tumor-associated surface antigens selected from CD19, CD20, CD30, a major histocompatibility complex (MHC) molecule, an Immunoglobulin (Ig), CD3, CD5, CD34, CD79, preferably CD79b, CD138, B7-1 (CD80), BCMA (CD269, TNFRSF 17), FLT-3, or PAX5, preferably CD19.
7. The UCART22 according to any one of claim 1 to 6 wherein said CD22CAR further comprises an antigen binding domain specific for CD19 or wherein said UCART 22 further comprises a CD19CAR, preferably a CD19 CAR having at least 80% identity with SEQ ID N°25 or a SEQ ID N°26.
8. The UCART22 according to any one of claim 1 to 7 wherein the anti-CD22 CAR is a single-chain CAR or a multi-chain CAR.
9. The UCART22 according to any one of claim 6 or 7 wherein the anti-CD19 CAR is a single-chain CAR or a multi-chain CAR.
10. A population of UCART cells comprising the UCART 22 according to any one of claim 1 to 9.
11. The population of UCART cells according to claim 10 comprising a UCART 19, preferably a UCART19 expressing an anti-CD19 CAR comprising a sequence of SEQ ID N°25 or SEQ. ID N°26 at the cell surface.
12. A kit comprising a UCART 22 and a UCART19 for a successive (at least once) or a concomitant or a successive (at least once) and then concomitant administration in a patient in need thereof.
13. The kit of claim 12 wherein the UCART 19 is used first at least once, twice, three, four or several times, and then the UCART 22, alone or with the UCART19.
14. The kit of claim 12 or 13 wherein the UCART 22 is used first at least once, twice, three, four or several times, and then the UCART 19, alone or with the UCART22.
15. The kit according to any one of claim 12 to 14 further comprising a lymphodepleting treatment, administered before the UCART.
16. The kit according to any one of claim 12 to 15 wherein lymphodepletion is achieved using fludarabine and cyclophosphamide, preferably fludarabine 25 mg / m2 i.v. × 5 doses on days -6 to -2 and cyclophosphamide 60 mg / kg i.v. for 1 dose on day -5.
17. The kit according to any one of claim 12 to 16 comprising at least one other UCART cell directed against a cancer antigen selected from CD79a, CD79b, CD20, CD30, CD52, CD40, CD80, CD86, CD74, VEGF.
18. A pharmaceutical composition comprising the UCART 22 according to any one of claim 1 to 9 or a population of cells comprising said UCART 22 according claim 10 or 11 and a pharmaceutically acceptable excipient.
19. The pharmaceutical composition of claim 18 further comprising a Bryostatin, preferably Bryostatin-1.
20. The pharmaceutical composition of claim 18 or 19 or the kit according to any one of claim 12 to 17 for its use as a medication for preventing or treating a patient suffering a CD22+-mediated cancer or a CD22+-mediated inflammatory disease.
21. The pharmaceutical composition of according to any one of claim 18 or 19 or the kit according to any one of claim 12 to 17 for its use as a medication for preventing or treating a patient suffering a CD19+-mediated cancer or a CD19+-mediated inflammatory disease.
22. The pharmaceutical composition of according to any one of claim 18 or 19 or the kit according to any one of claim 12 to 17 for its use as a medication for preventing or treating a patient suffering a CD19+CD22+-mediated cancer or a CD19+CD22+-mediated inflammatory disease.23.The pharmaceutical composition of according to any one of claim 18 or 19 or the kit according to any one of claim 12 to 17 for its use according any one of claim 20 or 22, wherein treating a patient comprises a step of administering the pharmaceuticalcomposition at least twice (re dosing) to avoid a relapse / refractory development of the cancer.
24. The pharmaceutical composition of according to any one of claim 18 or 19 or the kit according to any one of claim 12 to 17 for its use according any one of claim 20 or 22, for the treatment of a CD22-mediated hematological cancer selected from lymphoma, Hodgkin lymphoma, non Hodgkin lymphoma, leukemia, multiple myeloma, B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia (ALL), and Burkitt's lymphoma, acute lymphocytic cancer, acute myeloid leukemia, preferably a CD22 expressing hematological cancer selected from (lymphoma, Hodgkin lymphoma, non Hodgkin lymphoma, leukemia, multiple myeloma, B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia (ALL), and Burkitt's lymphoma, acute lymphocytic cancer, acute myeloid leukemia, more preferably a relapse refractory CD22-expressing hematological cancer, even more preferably an aggressive form of said CD22-related hematological cancer.
25. The pharmaceutical composition of according to any one of claim 18 or 19 or the kit according to any one of claim 12 to 17 for its use according any one of claim 21 or 22 for the treatment of a CD19-mediated hematological cancer selected from lymphoma, Hodgkin lymphoma, non Hodgkin lymphoma, leukemia, multiple myeloma, B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia (ALL), and Burkitt's lymphoma, acute lymphocytic cancer, acute myeloid leukemia, preferably a CD19 expressing hematological cancer selected from (lymphoma, Hodgkin lymphoma, non Hodgkin lymphoma, leukemia, multiple myeloma, B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia (ALL), and Burkitt's lymphoma, acute lymphocytic cancer, acute myeloid leukemia, more preferably a relapse refractory CD19-expressing hematological cancer, even more preferably an aggressive form of said CD19-related hematological cancer.
26. The pharmaceutical composition of according to any one of claim 18 or 19 or the kit according to any one of claim 12 to 17 for its use according any one of claim 20 to 23 for the treatment of a relapse or refractory expressing B ALL, preferably as a pediatric indication.
27. The pharmaceutical composition of according to any one of claim 18 or 19 or the kit according to any one of claim 12 to 17 for its use according any one of claim 20 to 26, wherein treating a patient comprises administering at least one monoclonal antibody (mAb), preferably QBEN 10 and or Rituximab, in a patient, at a dose allowing contacting said UCART22 with at least one specific mAb.
